1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

Seattle Genetics Wins 3rd Indication For Adcetris

 
• By Donna Young

Shares of Seattle Genetics rose $1.55, or 3.3%, in after-hours trading on Aug. 17 after the firm won a third US indication for its CD30-directed antibody-drug conjugate Adcetris (brentuximab vedotin) from an accelerated to a regular approval – classical Hodgkin lymphoma (HL) in patients at high risk of relapse or progression as post-autologous hematopoietic stem-cell transplantation (auto-HSCT) consolidation.

Shares of Seattle Genetics rose $1.55, or 3.3%, in after-hours trading on Aug. 17 after the firm won a third US indication for its CD30-directed antibody-drug conjugate Adcetris (brentuximab vedotin) from an accelerated to a regular approval – classical Hodgkin lymphoma (HL) in patients at high risk of relapse or progression as post-autologous hematopoietic stem-cell transplantation (auto-HSCT) consolidation.

The approval was based on data from Seattle Genetics' Phase III AETHERA study.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

Merus Bispecific Impresses In Head And Neck Cancer

 
• By Andrew McConaghie

Updated Phase II results from petosemtamab have impressed ahead of ASCO, outshining Keytruda monotherapy and its bispecific rival from Bicara.

Boehringer’s CMO On How AI, Integrated Evidence Generation Underpin Its Ambitious Launch Plans

 
• By Alexandra Shimmings

The German company has big plans for the next five years or so. Scrip speaks to its chief medical officer Lykke Hinsch Gylvin about how it is using AI and other innovative approaches to make good on its ambitions.

End Is Nigh For 4SC After EMA’s No For Kinselby

 
• By Kevin Grogan

The German biotech has discontinued the oral HDAC inhibitor for cutaneous T-cell lymphoma.

Japan Pharma Sees US Revenues Grow But Policy Impact Still Unclear

 
• By Lisa Takagi

Japanese majors put in generally solid performances in the fiscal year ended 31 March, but overseas revenues and forex effects, rather than the domestic market, provided most of the growth.

More from Therapy Areas